Skip Navigation

European Heart Journal 2001 22(15):1307-1310; doi:10.1053/euhj.2000.2540
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Otterstad, J.E
Right arrow Articles by Sleight, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otterstad, J.E
Right arrow Articles by Sleight, P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical Perspective

The HOPE study: Comparison with other trials of secondary prevention

J.E Otterstada,f1 and P Sleightb

a Department of Cardiology, Vestfold Central Hospital, Toensberg, Norway
b John Radcliffe Hospital, University of Oxford, Oxford, U.K.

revised November 13, 2000; accepted November 22, 2000

Abstract

No Abstract

Key Words: Prevention, HOPE study, treatment effect, ACE inhibition in heart failure, statin trials

f1 Correspondence: Jan Erik Otterstad MD, FESC. Division of Cardiology, Vestfold Central Hospital, N-3116 Toensberg, Norway.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CMAJHome page
F. A. McAlister MD MSc
The "number needed to treat" turns 20 -- and continues to be used and misused
Can. Med. Assoc. J., September 9, 2008; 179(6): 549 - 553.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
R. Roccaforte, C. Demers, F. Baldassarre, K. K.Teo, and S. Yusuf
Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis
Eur J Heart Fail, December 1, 2005; 7(7): 1133 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. E. Otterstad and I. Ford
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction: How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
Eur J Heart Fail, August 1, 2002; 4(4): 501 - 506.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J.E. Otterstad, M.G. St. John Sutton, G.S. Froeland, I. Holme, T. Skjaerpe, and C. Hall
Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function
Eur. Heart J., July 1, 2002; 23(13): 1011 - 1020.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.